The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success. Delgocitinib cream significantly improved chronic hand eczema in ...

Patients with CHE in the US extensively use corticosteroids and often experience increased costs with increased therapy intensity.

Chronic hand eczema is common, heterogeneous, and frequently occupational, with high rates of sick leave, job disruption, and notable annual per-patient societal costs in the United States. Diagnostic ...

A new study discovers a dedicated mechanical itch pathway linked to peach fuzz hairs, opening new targets for eczema treatment.

Please provide your email address to receive an email when new articles are posted on . Chronic hand eczema affects nearly one in 10 U.S. adults. Prevalence rates are highest among men, employed ...

Chronic hand eczema (CHE) is a condition separate from eczema, also known as atopic dermatitis, and has a prevalence rate of approximately 4.7% MADISON, N.J.--(BUSINESS WIRE)--Ninety-five percent (95% ...

Eczema is a group of inflammatory and chronic skin conditions, and it is the most common skin disease among older people. As many as one in two people aged over 60 suffer from some form of eczema. A ...

Please provide your email address to receive an email when new articles are posted on . In two phase 3 trials, delgocitinib cream improved hand eczema in a greater proportion of patients vs. vehicle.

Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor. Positive topline results were announced from a second phase 3 study evaluating delgocitinib cream in adult patients with moderate to ...

If you’ve ever experienced eczema, or you know someone who has, you’re probably familiar with the physical effects of itchy, irritated skin. But the chronic condition can take a major mental toll, too ...

Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials.

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, will present new data and insights in moderate-to-severe atopic dermatitis and chronic hand eczema at the ...